A PYMNTS Company

Multinational: Without new CEO, Teva Pharmaceuticals may look to merge

By  |  November 19, 2013

As Israel-based Teva Pharmaceuticals struggles to recuperate losses after one f its worst yearly performances, reports say the company may look to merge with counterparts within the US or Canada if it cannot find a new chief executive officer.

The generic drug maker may look to strike a deal with US-based Mylan Inc. or Canada-based Valeant Pharmaceuticals International. The company remains under threat, however, of a takeover by an activist investor, according to Matric Asset Advisors.

The company remains without a CEO as their last resigned last October; analysts are now awaiting the company’s next move.

A recently Supreme Court ruling places Teva in the line of fire for competition from rival generic drug makers producing Copaxone, a treatment for multiple sclerosis.

Full Content: Bloomberg

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.